Home World News Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in... World News Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane in Patients with Platinum-Resistant Epithelial Ovarian Cancer By Ogkologos - June 23, 2025 789 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Expanding the horizons of the life science economy May 3, 2022 GreaterGood Partners with Organization of Hope to Deliver Toys and Necessities... January 5, 2022 Reunión anual de la American Society of Clinical Oncology de 2023:... June 5, 2023 EMA Recommends Granting a Conditional Marketing Authorisation for Belantamab Mafodotin July 29, 2020 Load more HOT NEWS Epigenetic Changes Pinpointed as the Cause of Some GISTs Study Advances Fertility Preservation Approach for Male Cancer Survivors New Blood Test Can Screen For Over 50 Cancers New reports show staff shortages continue to hold back cancer care
